|
|
Halozyme Therapeutics Inc (HALO) |
|
Price: $39.6900
$1.08 
2.797%
|
| Day's High:
| $39.75
| Week Perf:
| -2.86 %
|
| Day's Low: |
$ 38.49 |
30 Day Perf: |
18.44 % |
| Volume (M): |
1,024 |
52 Wk High: |
$ 59.40 |
| Volume (M$): |
$ 40,643 |
52 Wk Avg: |
$41.31 |
| Open: |
$38.81 |
52 Wk Low: |
$29.85 |
|
|
| Market Capitalization (Millions $) |
5,322 |
| Shares
Outstanding (Millions) |
134 |
| Employees |
3,011 |
| Revenues (TTM) (Millions $) |
781 |
| Net Income (TTM) (Millions $) |
254 |
| Cash Flow (TTM) (Millions $) |
127 |
| Capital Exp. (TTM) (Millions $) |
17 |
Halozyme Therapeutics Inc
Halozyme Therapeutics Inc.
is a biotechnology company based in San Diego, California, whose mission is to develop and commercialize innovative therapies for the treatment of cancer and other chronic diseases.
Founded in 1998, the company is focused on creating novel pharmaceutical products that are designed to improve the lives of patients using its proprietary Enhanze drug delivery technology.
The company has established strategic collaborations with some of the world's leading pharmaceutical companies, including Roche, Pfizer, and Bristol-Myers Squibb.
The company's Enhanze technology platform is based on the use of an enzyme called hyaluronidase, which is designed to break down the extracellular matrix that surrounds tumor cells and other tissues, thereby allowing drugs to diffuse more easily into the target cells.
This approach has been shown to enhance the pharmacokinetics and therapeutic efficacy of a variety of drugs, including monoclonal antibodies and chemotherapy agents.
Halozyme Therapeutics has a robust pipeline of drug candidates that utilize this technology, including several clinical-stage products that are being evaluated in various oncology indications.
One of the company's most promising pipeline candidates is PEGPH20, a recombinant human hyaluronidase enzyme that is being developed for the treatment of pancreatic cancer.
PEGPH20 is currently in Phase III clinical trials, and the company is hoping to demonstrate that it can improve the outcomes for this notoriously difficult-to-treat disease.
In addition to its Enhanze platform, Halozyme Therapeutics is also involved in the development of other novel therapies, including immune-oncology agents and enzyme replacement therapies for rare diseases.
The company has a diverse intellectual property portfolio, with more than 400 issued patents and pending patent applications worldwide.
Overall, Halozyme Therapeutics Inc.
is a leading biotech company that is leveraging its innovative technology platform to develop new and exciting treatments for some of the most challenging diseases facing patients today.
The company has a strong track record of success, having brought several products to market already, and it seems poised to continue to be a major player in the biotech industry in the years to come.
Company Address: 12390 El Camino Real San Diego 92130 CA
Company Phone Number: 794-8889 Stock Exchange / Ticker: NASDAQ HALO
| HALO is expected to report next financial results on February 20, 2024. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Calidi Biotherapeutics Inc
The stockholders of were taken by surprise as the company reported unexpected modifications in revenue figures during the July to September 30, 2023 reporting season. While the markets display less concern about the current organizational and operational excellence of the Biotechnology and Pharmaceuticals company (CLDIsn), the shareholders are eagerly awaiting the development of new revenue sources to strengthen the company's financial position.
During the mentioned reporting period, CLDIs faced an operating deficit of $-7.221 million, indicating considerable financial challenges. This significant deficit has raised concerns among stakeholders, as the company is still in the early stages of its development. Investors are now emphasizing the urgency of generating new revenue streams, underscoring the importance of increasing capital to sustain business operations.
|
|
Xtant Medical Holdings Inc
Xtant Medical Holdings Inc Turns Profitable, Signaling Strong Growth Potential
BELGRADE, Mont., Oct. 12, 2023 - Xtant Medical Holdings Inc (NYSE American: XTNT), a global medical technology company specializing in surgical solutions for spinal disorders, has announced impressive financial results for the most recent fiscal period. The company's turnaround to a surplus has caught the attention of investors, with income per share standing at $0.07 compared to a loss of $0.03 per share a year ago. Furthermore, Xtant Medical Holdings Inc achieved a positive income per share of $0.02 in comparison to a loss of $0.02 per share in the preceding reporting period.
One of the key factors contributing to their success is the substantial revenue growth of 68.262%, reaching $24.33 million from $14.46 million in the same reporting period last year. Sequentially, the company also witnessed a notable improvement of 25.053% from $19.46 million. The surge in revenue reflects Xtant Medical Holdings Inc's strong market presence and the increasing demand for its products.
|
|
Instil Bio Inc
Date: November 14, 2023
Following the big players in the Biotechnology and Pharmaceuticals industry, some overlooked entities are reporting their financial numbers for the third quarter of 2023. Two such companies, TIL and Instil Bio Inc, have recently released their Q3 financial results, which reflect varying degrees of success and challenges within their respective operations.
TIL, a company focused on developing tumor infiltrating lymphocyte therapies for cancer treatment, reported an operating shortfall of $-66.716 million for Q3 2023. This decrease in performance is likely to raise concerns among investors who were eagerly hoping for improvements in TIL's business model during this period. TIL is expected to attract additional investments to support growth and strategy enhancements.
|
|
Semper Paratus Acquisition Corporation
The Biotechnology and Pharmaceuticals sector has been closely monitoring the third-quarter earnings of Semper Paratus Acquisition Corporation, one of the key players in the industry. Experts in the sector are currently analyzing the company's financial performance to gain insights into its future prospects.
According to the latest reports, Semper Paratus Acquisition Corporation recorded an operating deficit of $-0.605971 million during the July to September 2023 quarter. These figures are concerning, especially considering that the company had achieved an operating deficit of $0.198832 million during the same period in 2022. This indicates a deterioration in the company's overall financial health.
|
|
Ladrx Corporation
The stock market is an ever-evolving landscape, filled with opportunities for both investors and corporations alike. In the Biotechnology and Pharmaceuticals sector, some companies often go unnoticed, but they are now emerging with promising earnings. One such corporation is Ladrx Corporation, which recently reported a decrease in its operating shortfall for the third quarter of 2023.
In comparison to the third quarter of 2022, Ladrx Corporation's operating shortfall has significantly improved. Last year, the company experienced an operating shortfall of $-1.167527 million. However, this year, the shortfall has decreased to $-0.840313 million. These numbers serve as crucial signals for the state of Ladrx Corporation, indicating a positive trend in the company's financial performance.
|
| Per Share |
Current |
| Earnings (TTM) |
1.89 $ |
| Revenues (TTM) |
5.82 $
|
| Cash Flow (TTM) |
0.94 $ |
| Cash |
2.05 $
|
| Book Value |
1.86 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
1.89 $
|
| Revenues (TTM) |
5.82 $ |
| Cash Flow (TTM) |
0.94 $ |
| Cash |
2.05 $
|
| Book Value |
1.86 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
